Anas Younes, MD, on DLBCL: Phase III Trial Results
2018 ASH Annual Meeting & ExpositionAnas Younes, MD, of Memorial Sloan Kettering Cancer Center, discusses trial findings on ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in people with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (Abstract 784).
Related Videos
Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: Treatment Trial Results
Shaji K. Kumar, MD, of the Mayo Clinic, discusses phase III findings on daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone in people with newly diagn...
Alexander B. Pine, MD, PhD, on Practices and Preferences for Anticoagulant Therapy in Treating VTE
Alexander B. Pine, MD, PhD, of Yale School of Medicine, discusses a survey gathering data on health-care providers’ practices and preferences in using direct oral anticoagulant the...
Gilles A. Salles, MD, PhD, on DLBCL: Results From the L-Mind Treatment Trial
Gilles A. Salles, MD, PhD, of Centre Hospitalier Lyon Sud, discusses trial findings on the monoclonal antibody MOR208 combined with lenalidomide in people with relapsed or refracto...
Julie Vose, MD, MBA, and Loretta J. Nastoupil, MD, on Large B-Cell Lymphoma: Real-World Experience With CAR T-Cell Therapy
Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Loretta J. Nastoupil, MD, of The University of Texas MD Anderson Cancer Center, discuss find...
Laurie H. Sehn, MD, MPH, on DLBCL: Trial Results on the Prognostic Significance of MYC
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses a study by the Lunenburg Lymphoma Biomarker Consortium that confirmed previous reports...
